

# US Post Marketing Commitments/Requirements



Product/Compound	Description of Commitment	NDA Number	Agreement Date	Projected Completion Date	Status
Savaysa (edoxaban)	2852-1: Pediatric Development in VTE (AF waived) Single-dose PK/PD study	206316	01/08/2015	12/31/2021  Study Completed	Submitted on 01/28/22  *Pending FDA confirmation as fulfilled
Savaysa (edoxaban)	2852-2: Phase 3 multicenter, randomized, active control study of Edoxaban in pediatric patients with documented venous thromboembolism	206316	01/08/2015	6/30/2022	Delayed – submission targeted for 12/19/2022
ENHERTU (fam-trastuzumab deruxtecan- nxki), 100mg injection	3762-5 Provide data from a media fill run to support the use of the drug product specific container closure system.	761139	12/20/2019	1/2020	Submitted 01/09/2020 Pending :FDA downgraded this to PMC final report due within 12 mos. of submission

# US Post Marketing Commitments/Requirements

Product/ Compound	Description of Commitment	NDA Number	Agreement Date	Projected Completion Date	Status
<p>TURALIO (Pexidartinib) 200 mg Capsules</p>	<p>3673-1: Conduct a long-term trial to further evaluate the risk of hepatotoxicity in adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery, who are receiving pexidartinib. The trial will include laboratory, imaging, and pathologic assessments of patients who experience liver toxicity due to exposure to pexidartinib. The trial should enroll patients with an AST or ALT &gt; 3 x ULN with concomitant bilirubin &gt;2 x ULN, an isolated bilirubin &gt; 2 x ULN (excluding those with Gilbert's syndrome), or an isolated AST or ALT &gt; 10 x ULN. The trial should evaluate the mechanism of action of liver injury based on liver biopsy information, including a detailed assessment of changes in resident macrophage phenotype, based on marker status, as well as detailed characterization of other immune cell infiltrates. Submit cumulative, integrated safety analyses after 5 and 10 years of follow-up from an adequate number of patients to characterize the long-term risk of hepatic failure with pexidartinib. These safety evaluations should be adequate to inform labeling of patient populations at highest risk and to provide evidence-based dose modifications and monitoring recommendations.</p>	<p>211810</p>	<p>08/02/2019</p>	<p>06/2036</p>	<p>Ongoing</p>

# US Post Marketing Commitments/Requirements



Product/Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-2 Submit the integrated immunogenicity summary report for all patients with solid tumors in clinical studies treated with DS-8201a, including the ongoing Phase 3 trials, having an immunogenicity component. The final report should include anti-drug antibody (ADA) results from screening, confirmatory, titering, domain specificity, and neutralization assays, the results of linear or non-linear correlation analyses between ADA status and titers with PK, PD, efficacy, and safety (adverse event) data. Submit the Integrated Immunogenicity Summary Report in accordance with Section VIII Documentation of the 2019 FDA Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products — Developing and Validating Assays for Anti-Drug Antibody Detection	761139	12/20/2019	6/2023	Ongoing
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-8 Perform the dye ingress method validation for container closure integrity testing of the drug product stability samples using positive controls with a $\leq 20$ micro breach size.	761139	12/20/2019	6/2020	Submitted 06/24/2020; Pending FDA Response

# US Post Marketing Commitments/Requirements



Product/Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-11 Confirm that the potency of the current DS-8201a primary reference standard 164RS03 and secondary reference standard 164WS01 is precise and accurate by conducting additional qualification of potency for primary reference standard 164RS03 using a sufficient number of independent assays and replicates. The number of independent assays and replicates will be scientifically justified. The qualification data will be reported as per 21 CFR 601.12.	761139	12/20/2019	2/2020	Submitted 2/20/2020  Pending: FDA downgraded this to PMC final report due within 12 mos. of submission
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-12 Confirm that the potency of MAAL-9001 primary reference standard 159RS02 is precise and accurate by conducting additional qualification of potency of primary reference standard 159RS02 using a sufficient number of independent assays and replicates. The number of independent assays and replicates will be scientifically justified. The qualification data will be reported as per 21 CFR 601.12.		12/20/2019	2/2020	Submitted 02/20/2020  Pending: FDA downgraded this to PMC final report due within 12 mos. of submission

# US Post Marketing Commitments/Requirements



Product/Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-13 Strengthen the qualification of the current MAAL-9001 primary and secondary reference standards by conducting additional characterization studies including full glycan profile analysis and FcγRIIIA binding activity of MAAL-9001 primary reference standard 159RS02 and secondary reference standard ST01-01 to support the use of these reference standards in comparability assessments. The qualification data will be reported as per 21 CFR 601.12	761139	12/20/2019	2/2020	Submitted 02/20/2020  Pending :FDA downgraded this to PMC final report due within 12 mos. of submission
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-14 Strengthen the qualification of the DS-8201a primary and secondary reference standards by conducting characterization of FcγRIIIA binding activity for primary reference standard 164RS03 to support the use of these reference standards in comparability assessments. The qualification data will be reported as per 21 CFR 601.12.	761139	12/20/2019	2/2020	Submitted 02/20/2020  Pending :FDA downgraded this to PMC final report due within 12 mos. of submission

# US Post Marketing Commitments/Requirements

Product/Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-15 Re-evaluate intermediate precision for the protein concentration and glycan analysis methods at Daiichi Sankyo Tatebayashi Plant, and for protein concentration, non-proteinaceous impurities (NPI) and purity of payload (PoP) methods for DS-8201a drug substance at Daiichi Sankyo Onahama Plant and report will be reported as per 21 CFR 601.12.	761139	12/20/2019	3/2020	Submitted 03/20/2020  Pending FDA Response
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-16 Develop and validate a neutralizing antibody assay to test confirmed anti DS-8201a antibody positive samples from studies J101, J102, A103, A104, and U201 as well as the ongoing Phase 3 clinical studies U301, U302, and U303.	761139	12/20/2019	6/2020	Submitted 06/19/2020  Pending FDA Response

# US Post Marketing Commitments/Requirements

Product/Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	3762-17 Develop and validate domain specificity assays to test confirmed anti-DS 8201a antibody positive samples from studies J101, J102, A103, A104, and U201 as well as the ongoing phase 3 clinical studies U301, U302, and U303. Specifically, the assays should determine the specificity of anti-DS 8201a antibodies for the monoclonal antibody MAAL-9001, the drug MAAA-1181a, and the linker.	761139	12/20/2019	12/2020	Submitted 12/18/2020  Pending FDA Response
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	4318-2 Commitment to support the availability, through appropriate analytical and clinical validation studies using the DESTINY-Breast04 clinical trial or other data adequate to support labeling, of an in vitro diagnostic device that is essential to the safe and effective use of fam-trastuzumab deruxtecan-nxki for treatment of patients with HER2-low advanced or metastatic breast cancer.	761139	08/05/2022	03/2024	Fulfilled on 11/04/2022 (with S-024 approval)

# US Post Marketing Commitments/Requirements

Product/ Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	<p>4269-1 Conduct the interim and final OS analysis for clinical study DESTINYBreast03 (NCT03529110) entitled “A Phase 3, multicenter, randomized, open-label, active-controlled study of T-DXd, an anti-HER2-antibody drug conjugate, versus T-DM1 for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane”, to further confirm the clinical benefit of T-DXd in this setting.</p> <ul style="list-style-type: none"> <li>• Interim Report Submission: 04/2023</li> <li>• Trial Completion: 09/2026</li> <li>• Final Report Submission: 03/2027</li> </ul>	761139	05/04/2022	03/2027	Ongoing



# US Post Marketing Commitments/Requirements

Product/ Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	<p>4318-1 Conduct an integrated analysis containing data from clinical trials and other data sources such as post-marketing reports, real-world evidence and other sources to further characterize the safety and efficacy of T-DXd in racial and ethnic minority patients and older patients age &gt;65 years with HER2-low metastatic breast cancer. The analyses should support comparative safety and efficacy outcome analyses between the aforementioned populations and White and younger patients.</p> <p>The timetable you submitted on August 1, 2022, states that you will conduct this study according to the following schedule:</p> <ul style="list-style-type: none"> <li>• Draft Protocol Submission: 05/2023</li> <li>• Final Protocol Submission: 12/2023</li> <li>• Trial Completion: 12/2026</li> <li>• Final Report Submission: 09/2027</li> </ul>	761139	08/05/2022	09/2027	Ongoing

# US Post Marketing Commitments/Requirements

Product/ Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	<p>4321-1 Complete a clinical trial to obtain data on the clinical efficacy of fam-trastuzumab deruxtecan nxki for the treatment of patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have an activating HER2 (ERBB2) mutation and have previously received systemic therapy, to provide a more precise estimation of the blinded independent central review-assessed overall response rate and duration of response. This report will contain data from patients with NSCLC harboring HER2 mutations and data from at least 102 patients who have received prior systemic therapy, after all responders have been followed for at least 6 months from the date of initial response (or until disease progression, whichever comes first).</p> <ul style="list-style-type: none"> <li>• Draft Protocol Submission: 11/2022</li> <li>• Final Protocol Submission: 02/2023</li> <li>• Trial Completion: 09/2023</li> <li>• Final Report Submission: 03/2024</li> </ul>	761139	08/05/2022	03/2024	Ongoing  – Draft Protocol submission completed

# US Post Marketing Commitments/Requirements

Product/ Compound	Description of Commitment	BLA Number	Agreement Date	Projected Completion Date	Status
ENHERTU (fam-trastuzumab deruxtecan-nxki), 100mg injection	<p>4321-2 Conduct a multicenter, randomized clinical trial of fam-trastuzumab deruxtecan-nxki in patients with treatment-naïve, unresectable or metastatic non-small cell lung cancer whose tumors have an activating HER2 (ERBB2) mutation. The final analysis should include the final progression-free survival and overall survival results.</p> <ul style="list-style-type: none"> <li>• Final Protocol Submission: 07/2021 (completed)</li> <li>• Trial Completion: 03/2028</li> <li>• Final Report Submission: 09/2028</li> </ul>	761139	08/11/2022	09/2028	Ongoing